Latest news with #SeriesD
Time of India
a day ago
- Business
- Time of India
Elon Musk's Neuralink implants brain chip in sixth patient who says 'I'm already shocked'
Neuralink, Elon Musk's brain-chip company, has implanted its brain-computer interface (BCI) in a sixth person. The update came from Rob Grenier, who shared his experience on social media platform X (formerly Twitter) earlier this week. "Absolutely amazing what I can do already in under a week with Neuralink!" Grenier posted, along with a video showing him playing a computer game and moving a cursor using only his thoughts. Grenier became quadriplegic after a car accident in December 2022. The incident left him paralyzed from the neck down. 'I can't thank the Neuralink team, the doctors, the surgeons and all of my family and friends' support. It may only look like I'm doing a couple games but it's been under a week and I'm already shocked!' he added in the post. Elon Musk's Neuralink raises $650 million in Series E round The announcement comes as Neuralink raised over $650 million in its Series E funding round, bringing its valuation to $9 billion. The Series E round attracted major investors including ARK Invest, Founders Fund, Sequoia Capital, Thrive Capital, and several others, valuing the company at approximately $9 billion pre-money according to recent reports. Cathie Wood's ARK Invest is among the company's major backers. The funding represented a significant increase from Neuralink's $280 million Series D round in August 2023. Neuralink has launched clinical trials at leading medical institutions across three countries, including Barrow Neurological Institute, The Miami Project to Cure Paralysis at the University of Miami, University Health Network in Toronto, and Cleveland Clinic Abu Dhabi. It is now preparing for a human trial of its Blindsight chip in partnership with the UAE's Cleveland Clinic in 2026. Musk had earlier said, 'With Neuralink interfacing directly to the visual cortex, even those who are completely blind will be able to see again.' Alcatel V3 Ultra Unboxing & Hands-on | Dual Display Mode, Sleek Design & More!
Entrepreneur
6 days ago
- Business
- Entrepreneur
SarvaGram Raises INR 565 Crore in Series D; Doubles Valuation to INR 1,785 Crore
SarvaGram's board approved the issuance of 21,857 Series D compulsorily convertible preference shares (CCPS) and 20 equity shares at INR 2,51,431.22 per share in November 2023 You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Rural-focused credit startup SarvaGram has raised INR 565 crore (approximately $67 million) in its Series D funding round, led by Peak XV Partners with participation from existing investors Elevation Capital, Elevar Equity, Temasek, and TVS Capital. While the company announced the round publicly, regulatory filings accessed by Entrackr revealed the detailed structure, shareholding changes, and valuation impact of the investment. According to documents filed with the Registrar of Companies, SarvaGram's board approved the issuance of 21,857 Series D compulsorily convertible preference shares (CCPS) and 20 equity shares at INR 2,51,431.22 per share in November 2023. This allotment accounted for INR 550 crore of the round, with a prior infusion of INR 15 crore bringing the total to INR 565 crore. Peak XV Partners led the round with an investment of INR 340 crore ($40.3 million). Existing backers followed suit—Elevation Capital put in INR 80.76 crore ($9.58 million), Elevar Equity contributed INR 68 crore ($8 million), while Temasek and TVS Capital invested INR 45.48 crore ($5.4 million) and INR 30.78 crore ($3.6 million) respectively. The funding has significantly boosted SarvaGram's valuation, which now stands at INR 1,785 crore ($212 million)—more than double its INR 790 crore ($94 million) valuation at the time of its $35 million Series C round. Founded in 2019 by Utpal Isser and Sameer Mishra, SarvaGram focuses on delivering tailored credit and financial services to rural households, including business, farm, personal, home, and gold loans. The company also offers farm mechanization and insurance through its SarvaMitra network, which spans over 38,000 villages, supporting more than 1.5 lakh households and over 170 retail outlets. Data from TheKredible shows SarvaGram has raised over $116 million across multiple rounds. Post-Series D, Elevar Equity remains the largest external shareholder with a 23.78 per cent stake, followed by Peak XV Partners (19.05 per cent) and Elevation Capital (18.40 per cent). Co-founders Isser and Mishra continue to hold 11.00 per cent and 7.05 per cent, respectively. Financially, the Pune-based fintech reported a 2.3x growth in operating revenue to INR 170 crore for the year ending March 2024. Losses narrowed by 30 per cent year-on-year to INR 19.75 crore. SarvaGram faces competition from agri-fintech startups such as Jai Kisan, which last raised $50 million, and which secured $30 million in debt funding earlier this year.
Axios
6 days ago
- Business
- Axios
Exclusive: Horizon3.ai raises $100M Series D
Autonomous security startup locked up a $100 million Series D led by NEA, co-founder and CEO Snehal Antani tells Axios Pro. Why it matters: AI is making cyberattacks faster and more sophisticated — and is aiming to even the playing field. How it works: penetration testing platform — NodeZero — uses AI to find and exploit attack paths in production systems so teams can fix issues. The platform also collects training data used to improve its own algorithms and increase defenses. Zoom in: SignalFire, Craft Ventures and 9Yards Capital also participated in the round, which brings the company's total funding to $180 million. By the numbers: is experiencing 100% ARR growth year to year and is now Rule of 40-positive. The startup's platform is used by 3,000 organizations — including national defense partners — and is more than doubling its customer base annually. State of play: The penetration testing market seems to be attracting investors. Strike Security raised a $13.5 million Series A led by FinTech Collective in March. Threat level: A recent survey found that almost 74% of participants say AI-powered threats are a major challenge for their company.
Yahoo
12-06-2025
- Business
- Yahoo
Wandercraft raises $75m in funding to introduce self-balancing exoskeleton
Robotics company Wandercraft has raised $75m in a Series D funding round to introduce the self-balancing personal exoskeleton, Eve, to market by 2026. This investment will fuel the company's growth and the expansion of its flagship rehabilitation system, Atalante X, which received FDA clearance. After receiving second clearance, Atalante X's use was expanded to US hospitals and clinics. It will also support the development and deployment of Calvin-40, Wandercraft's humanoid robot. The Series D round saw significant contributions from Renault Group, PSIM fund, Quadrant Management, and Teampact Ventures, among others. Since its last funding round, Wandercraft has experienced substantial growth, with a tenfold revenue increase propelled by the commercial expansion in the US. The Series D funding follows a strategic partnership and minority stake acquisition by Renault Group, which will leverage its industrial know-how to scale up production of exoskeletons and robots of Wandercraft. This industrial-grade robot, capable of performing physically demanding tasks, is said to have been developed in just 40 days using Wandercraft's quick development process and integrated with NVIDIA's Isaac technologies. Wandercraft co-founder and CEO Matthieu Masselin said: "The momentum we've achieved over the past few years is extraordinary. 'We've expanded globally, launched pivotal clinical trials, readied the commercialisation of Eve, our personal exoskeleton, and entered a landmark partnership with Renault Group.' Wandercraft's Atalante X is currently leveraged to assist individuals with disabilities in over 100 rehabilitation centres across four continents. The introduction of Eve aims to aid the users of wheelchairs by enabling standing and walking in daily life. "Wandercraft raises $75m in funding to introduce self-balancing exoskeleton" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
12-06-2025
- Business
- Yahoo
Wandercraft raises $75m in funding to introduce self-balancing exoskeleton
Robotics company Wandercraft has raised $75m in a Series D funding round to introduce the self-balancing personal exoskeleton, Eve, to market by 2026. This investment will fuel the company's growth and the expansion of its flagship rehabilitation system, Atalante X, which received FDA clearance. After receiving second clearance, Atalante X's use was expanded to US hospitals and clinics. It will also support the development and deployment of Calvin-40, Wandercraft's humanoid robot. The Series D round saw significant contributions from Renault Group, PSIM fund, Quadrant Management, and Teampact Ventures, among others. Since its last funding round, Wandercraft has experienced substantial growth, with a tenfold revenue increase propelled by the commercial expansion in the US. The Series D funding follows a strategic partnership and minority stake acquisition by Renault Group, which will leverage its industrial know-how to scale up production of exoskeletons and robots of Wandercraft. This industrial-grade robot, capable of performing physically demanding tasks, is said to have been developed in just 40 days using Wandercraft's quick development process and integrated with NVIDIA's Isaac technologies. Wandercraft co-founder and CEO Matthieu Masselin said: "The momentum we've achieved over the past few years is extraordinary. 'We've expanded globally, launched pivotal clinical trials, readied the commercialisation of Eve, our personal exoskeleton, and entered a landmark partnership with Renault Group.' Wandercraft's Atalante X is currently leveraged to assist individuals with disabilities in over 100 rehabilitation centres across four continents. The introduction of Eve aims to aid the users of wheelchairs by enabling standing and walking in daily life. "Wandercraft raises $75m in funding to introduce self-balancing exoskeleton" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
